このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
BioMarin Pharmaceutical バランスシートの健全性
財務の健全性 基準チェック /66
BioMarin Pharmaceuticalの総株主資本は$5.1B 、総負債は$1.1Bで、負債比率は21.4%となります。総資産と総負債はそれぞれ$6.9Bと$1.8Bです。 BioMarin Pharmaceuticalの EBIT は$188.2Mで、利息カバレッジ比率-3.9です。現金および短期投資は$1.0Bです。
主要情報
21.4%
負債資本比率
US$1.09b
負債
| インタレスト・カバレッジ・レシオ | -3.9x |
| 現金 | US$1.05b |
| エクイティ | US$5.07b |
| 負債合計 | US$1.80b |
| 総資産 | US$6.87b |
財務の健全性に関する最新情報
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25Recent updates
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10財務状況分析
短期負債: BMRNの 短期資産 ( $3.0B ) が 短期負債 ( $1.1B ) を超えています。
長期負債: BMRNの短期資産 ( $3.0B ) が 長期負債 ( $711.0M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: BMRNの 純負債対資本比率 ( 0.8% ) は 満足できる 水準であると考えられます。
負債の削減: BMRNの負債対資本比率は、過去 5 年間で28.4%から21.4%に減少しました。
債務返済能力: BMRNの負債は 営業キャッシュフロー によって 十分にカバー されています ( 25.8% )。
インタレストカバレッジ: BMRN支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。